The first of this class of products, Strimvelis®, received marketing authorization in Europe in 2016 for the treatment of patients with severe combined immunodeficiency caused by adenosine deaminase deficiency (ADA-SCID) lacking an HLA-matched related stem cell donor. This evidence concerns the gene ADA and hyperinsulinemic hypoglycemia, familial, 4.